F-1/A: NewGenIvf Group Limited Plans Resale of Up to 139.4 Million Class A Ordinary Shares

Selling shareholders of NewGenIvf Group Limited intend to resell up to 139,425,259 Class A Ordinary Shares, according to a recent filing.

Summary

• NewGenIvf Group Limited has filed a registration statement for the resale of up to 139,425,259 Class A Ordinary Shares by selling shareholders.
• These shares consist of shares issuable upon conversion of senior convertible notes and exercise of warrants.
• The notes were issued on August 12, 2024, and August 28, 2024.
• The warrants include Series A, Series B, and Exchange Warrants.
• The company will not receive any proceeds from the sale of these shares by the selling shareholders.
• However, NewGenIvf will receive proceeds from the exercise of the warrants if exercised for cash, which will be used for working capital and general corporate purposes.
• The selling shareholders aim to enhance liquidity in the public trading market for the company's equity securities.
• The company's Ordinary Shares currently trade on The Nasdaq Global Market under the symbol NIVF.
• The last reported closing price of the Ordinary Shares on August 30, 2024, was $0.86.
• As of September 4, 2024, the number of Ordinary Shares currently issued and outstanding was 10,149,386.
• No new shares are being issued by the Company pursuant to this offering.

Sentiment

Score: 5

Explanation: The document is primarily a registration statement for the resale of shares, presenting factual information. While it includes risk factors, it also highlights growth strategies and market opportunities, resulting in a neutral sentiment.

Positives

• The resale of shares by selling shareholders aims to enhance liquidity in the public trading market.
• Proceeds from warrant exercises will be used for working capital and general corporate purposes.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling shareholders.
• The market price of the Ordinary Shares could be depressed by the sale of securities in the public market by the Selling Securityholders.

Risks

• Investing in the company's Class A Ordinary Shares involves a high degree of risk.
• The company may not be able to continue operating as a going concern.
• The fertility market is competitive, which could adversely affect the company's results of operations.
• The company has a limited operating history with its current platform of solutions.
• The company's marketing efforts depend significantly on positive references from existing clients.
• The company's business depends on maintaining its existing client demographics.
• The company may experience net losses and may not sustain profitability in the future.
• The company's future revenue may not grow at the rates it historically has, or at all.
• The company's quarterly and annual results may fluctuate significantly.
• The estimates and assumptions used to determine the size of the target markets may be inaccurate.
• The company may not be able to successfully manage its growth.
• New solutions and services may not be adopted by clients.
• The company may fail to adapt to the changing medical landscape.
• The company may fail to maintain and enhance its brand.
• The company may fail to retain and motivate key employees.
• The company must address many international business risks.
• Ethical, legal, and social concerns related to assisted reproductive technology could reduce demand.
• The company is reliant on revenue from international clients.
• Fluctuations in exchange rates could have a material and adverse effect.
• Governmental control of currency conversion may limit the company's ability to utilize net revenue.
• Substantially all of the company's assets and operations are located in Thailand, Cambodia, and Kyrgyzstan.
• Failure to comply with the terms of future financing arrangements could result in default.
• The company requires a significant amount of capital to fund its operations and growth.
• Defects in certain leased property interests and failure to register certain lease agreements may materially and adversely affect the company.
• The company currently has no insurance coverage for its operations.
• The company may not be successful in adapting to technological developments.
• If its computer systems fail or suffer security breaches, the company may incur a material disruption of its services.
• The company may not be able to comply with the filing deadlines for reports that it files pursuant to the Exchange Act.
• If the company is unable to continue to meet the listing requirements of Nasdaq, its Class A Ordinary Shares will be delisted.

Future Outlook

The company intends to provide broad fertility services for fertility tourists, continue to invest in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships.

Industry Context

The document highlights the growing assisted reproductive services (ARS) market in Asia Pacific, driven by factors such as societal shifts, cultural acceptance, and increasing infertility rates. The company aims to address key challenges in the Asia-Pacific fertility industry, including financial constraints and limited access to treatment.

Comparison to Industry Standards

• According to CIC, the average cost per IVF cycle in the US is around US$12,000 (excluding medication), which is 65% higher than that of Asia-Pacific market.
• Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication).

Related Party Transactions

• NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.

Stakeholder Impact

• The resale of shares by selling shareholders may affect the market price of the company's Ordinary Shares.
• The company's performance and growth strategies will impact shareholders, employees, customers, and other stakeholders.

Next Steps

• The selling shareholders may sell all or a portion of the Ordinary Shares from time to time in market transactions, negotiated transactions, or otherwise.
• The company will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash, which proceeds will be used for working capital and other general corporate purposes.

Key Dates

Keywords

Ordinary Shares, NewGenIvf, Resale, Convertible Notes, Warrants, Selling Shareholders, Liquidity, NIVF, Nasdaq, Fertility